Assess whether the primary endpoint will survive FDA scrutiny (81ff72)

SITUATION After an FAERS cluster in a demographic the trials under-enrolled, biosimilar analytical similarity report is what RWE evidence-strategy director can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. An FAERS cluster in a demographic the trials under-enrolled is noise around an already-controlled Pharmacovigilance process in an RWE group proposing a post-marketing study instead of a new RCT, given biosimilar analytical similarity report. 2. An FAERS cluster in a demographic the trials under-enrolled is the event in biosimilar analytical similarity report that forces Proceed under protocol for RWE evidence-strategy director under Pharma & Life Sciences. 3. Biosimilar analytical similarity report shows a one-file miss after an FAERS cluster in a demographic the trials under-enrolled, not a Pharmacovigilance program failure. 4. Biosimilar analytical similarity report cannot decide the primary endpoint will yet after an FAERS cluster in a demographic the trials under-enrolled; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

ANALYSIS REQUIRED 1. Check whether biosimilar analytical similarity report supports the labeled claim RWE evidence-strategy director would keep. 2. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 3. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the primary endpoint will for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled). If biosimilar analytical similarity report cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences Pharmacovigilance close, RWE evidence-strategy director must state the unresolved clinical or safety evidence requirement explicitly.